Oracle’s Research Advisory Committee
The role of Oracle’s research committee is to review applications received from a wide range of academic institutions throughout the UK and evaluate their promise in terms of leading to mainstream funding and the likelihood of entering into the clinic as trials. Unfortunately, mainstream medical research funders will not consider projects that do not have a proof of concept, and this is why Oracle’s role in funding these early-stage “seed” trials are so vital.
Oracle’s research committee is wholly independent, voluntary, and is Chaired by leading City financier and Oracle Trustee Keith Jones, Oncologist Dr John Glaholm, ENT Surgeon Dr Stuart Winter and Oncologist Dr Ketan Shah.
The committee meets up to four times a year, to review new applications and appraise all current research projects to ensure that they continue to meet with Oracle’s stringent funding and research criteria.